Latest News
Investor Relations
Latest News
April 21, 2025 07:07 am
BioStem Technologies to Present at the Centri Capital Conference
April 14, 2025 04:14 pm
BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million
April 8, 2025 07:00 am
BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025
April 1, 2025 04:49 pm
BioStem Technologies Announces Extension to File 2024 Annual Report with OTC
March 31, 2025 07:00 am
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
March 27, 2025 07:00 am
BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference
February 24, 2025 07:00 am
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers
January 13, 2025 07:00 am
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million
January 8, 2025 07:00 am
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
January 2, 2025 07:00 am